Viral Hepatitis Market: By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, and Others), By Treatment (Vaccines, Antiviral Drugs, Immune Modulator Drugs, and Surgery), By Diagnosis (Liver Biopsy, Blood Tests, and Imaging Tests), By Route of Administration (Oral, Parenteral, and Others), By End User (Hospitals, Specialty Clinics, and Homecare Settings), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography

Viral Hepatitis Market size was valued at USD 13.97 in 2023 and is poised to grow at a significant CAGR 3.10% from 2024 to 2030. The development of highly effective and well-tolerated antiviral medications, particularly for Hepatitis C, has revolutionized treatment. This not only improves patient outcomes but also encourages wider treatment adoption. In addition, combination therapies that combine multiple antiviral drugs are increasingly being used for Hepatitis B and C, leading to higher cure rates and shorter treatment durations. This drives demand for these specialized drugs. The availability of generic antiviral drugs, particularly for Hepatitis C, has significantly reduced treatment costs. This makes treatment more accessible to patients in developing countries. Moreover, many governments are implementing national programs for Hepatitis B vaccination and treatment, aiming to achieve elimination goals.

This creates a sustained demand for vaccines and medications. Also, rapid, easy-to-use point-of-care diagnostic tests can facilitate early diagnosis and treatment initiation, especially in remote areas with limited healthcare infrastructure. Telemedicine platforms can also improve access to specialist care and treatment management for patients in geographically dispersed regions. Furthermore, combating stigma associated with viral hepatitis is crucial. Public health campaigns promoting awareness and understanding can encourage people to come forward for testing and treatment. Patient advocacy groups play a vital role in raising awareness about the disease and advocating for improved access to care. However, many developing countries lack the infrastructure and resources needed to effectively manage viral hepatitis. This includes a shortage of trained healthcare professionals, diagnostic equipment, and treatment facilities.

Viral Hepatitis Market Key Developments:

• In March 2021, US based biopharmaceutical company, Gilead Sciences Inc., acquired MYR GmbH which is a Germany based developer and manufacturer of treatments for chronic hepatitis B and D viral diseases for $ 1.60 billion. This acquisition offers Gilead with Hepcludex, which the European Medicines Agency has provisionally licensed for treating chronic hepatitis delta virus in people with compensated liver disease.